Related Experiment Video
Updated: Feb 13, 2026
05:17
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
428
Cetuximab for treating non-small cell lung cancer
Luca Mazzarella1, Alessandro Guida1, Giuseppe Curigliano1
1a University of Milano, Department of Oncology and Hemato-Oncology, Division of Early Drug Development for Innovative Therapies , European Institute of Oncology , Milano , Italia.
Expert Opinion on Biological Therapy
|March 15, 2018
Summary
Cetuximab, an EGFR-targeting antibody, shows limited benefit in non-small cell lung cancer (NSCLC) due to a lack of predictive biomarkers. Future use may depend on identifying specific patient subsets.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Epidermal Growth Factor Receptor (EGFR) signaling is vital in epithelial cancers, driving targeted therapy development.
- Cetuximab, a chimeric antibody, is established in colorectal and head and neck cancers.
- Cetuximab's efficacy in non-small cell lung cancer (NSCLC) remains limited despite Phase III trials.
Purpose of the Study:
- To review the literature on EGFR as a therapeutic target.
- To examine Cetuximab's development, pharmacodynamics, pharmacokinetics, and clinical trials in NSCLC.
- To focus on recent findings regarding predictive biomarkers for Cetuximab response in NSCLC.
Main Methods:
- Literature review of basic science, pharmacology, and clinical trials.
- Analysis of Cetuximab's clinical utility and development in NSCLC.
- Evaluation of emerging predictive biomarkers for patient selection.
Main Results:
- Cetuximab has not achieved routine clinical practice in NSCLC.
- Marginal clinical benefit observed in NSCLC trials despite statistical significance.
- Recent data suggests potential benefit in carefully selected patient subsets based on molecular markers.
Conclusions:
- Cetuximab currently lacks a role in NSCLC treatment outside of clinical trials.
- Failure to identify predictive biomarkers early hampered Cetuximab's integration into NSCLC practice.
- Regulatory approval and competition limit Cetuximab's potential impact even in selected NSCLC patient groups.
Related Concept Videos
01:47Lung Capacity
56.4K
The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.4K
01:35Cancer Cell Migration through Invadopodia
3.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.3K
02:53Adaptive Mechanisms in Cancer Cells
7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
01:13Pleura of the Lungs
7.7K
The lungs are nestled in a cavity, shielded by the pleura. The pleura, a form of serous membrane, wraps around each lung. This membrane arrangement consists of two layers: the visceral and parietal pleurae. The visceral pleura lines the surface of the lungIn contrast, the parietal pleura is the outer layer and contacts to the thoracic wall, the mediastinum, and the diaphragm. The hilum is the point of connection between the visceral and parietal layers. The space between the parietal and...
7.7K
02:40Cancer Stem Cells and Tumor Maintenance
6.1K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.1K
02:21Cancers Originate from Somatic Mutations in a Single Cell
15.0K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.0K